ReviewOncoimmunology2016
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.
Review in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Recent advances and future prospects of immunotherapeutic approaches in prostate cancer.Journal of translational medicine · 2026Review
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Review
- Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T.Prostate cancer · 2025Review
- Delivery strategies of cancer immunotherapy: recent advances and future perspectives.Journal of hematology & oncology · 2019Review
- Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.JAMA network open · 2019Article
- Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.Molecular diagnosis & therapy · 2018Article
- Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer.Journal of Cancer · 2018Article
- CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal.Central-European journal of immunology · 2018Article
- Immunotherapy for Prostate Cancer: Where We Are Headed.International journal of molecular sciences · 2017Review
- Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?Current opinion in urology · 2017Review
- Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring.Journal of translational medicine · 2017Article
- Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.JCI insight · 2017Article
- Review
- Potential applications of nanoparticles in cancer immunotherapy.Human vaccines & immunotherapeutics · 2017Review
- Monitoring of the Immune Dysfunction in Cancer Patients.Vaccines · 2016Review
- Review
- Review
- Review
- Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Il Giornale di chirurgiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.